We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Urge Approval of Abbott’s Humira for Ulcerative Colitis
FDA Advisers Urge Approval of Abbott’s Humira for Ulcerative Colitis
August 31, 2012
Despite “fragile” trial data, the FDA should approve Abbott Laboratories’ proposed new indication for its blockbuster Humira to treat ulcerative colitis (UC) because new therapies for the chronic condition are needed and clinicians are comfortable with the drug’s safety profile, agency advisers say.